UBS Group
ASND icon

UBS Group’s Ascendis Pharma A/S ASND Stock Holding History

UBS Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,000
Closed -$589K – 7841
2019
Q1 		$589K Buy
+5,000
New +$438K ﹤0.01% 3957

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group's ASND Position: Q1 2026 in Review

UBS Group reduced its Ascendis Pharma A/S (ASND) stake by 33% in Q1 2026, selling an estimated $22.6M and leaving 207,339 shares worth $47.4M. The position accounts for 0.01% of the portfolio, ranked #1698.

UBS Group first reported a position in ASND in Q1 2015 and has held it in 42 quarters since. The position peaked at $65.7M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • UBS Group held 207,339 shares of Ascendis Pharma A/S worth $47.4M as of Q1 2026.
  • UBS Group sold 100,851 Ascendis Pharma A/S shares in Q1 2026, an estimated $22.6M.
  • Ascendis Pharma A/S made up 0.01% of UBS Group's portfolio in Q1 2026, its #1698 holding.
  • UBS Group first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 42 quarters since.
  • UBS Group's Ascendis Pharma A/S position peaked at $65.7M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.